Cellectis publishes promising non-viral gene therapy method for sickle cell disease using TALEN® technology.

Cellectis, a clinical-stage biotech company, published a non-viral gene therapy approach for sickle cell disease in Nature Communications. Leveraging TALEN® technology and non-viral gene repair templates, they develop a method for efficient HBB gene correction in hematopoietic stem and progenitor cells (HSPCs). Preclinical data shows promising results, paving the way for potential therapeutic applications in patients with sickle cell disease.